|
Volumn 15, Issue 9, 2004, Pages 1444-1445
|
Cyclooxygenase-2 inhibitor and cisplatin combination as a radiosensitizer in the treatment of head and neck cancer patients [2]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CISPLATIN;
CYCLOOXYGENASE 2;
CYCLOOXYGENASE 2 INHIBITOR;
N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE;
RADIOSENSITIZING AGENT;
TILMACOXIB;
CANCER CHEMOTHERAPY;
CANCER PATIENT;
CANCER RADIOTHERAPY;
CANCER SURVIVAL;
DRUG MECHANISM;
DRUG POTENTIATION;
HEAD AND NECK CANCER;
HIGH RISK PATIENT;
HUMAN;
LARYNX CANCER;
LETTER;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
RADIOSENSITIVITY;
STATISTICAL ANALYSIS;
TREATMENT FAILURE;
|
EID: 4644313842
PISSN: 09237534
EISSN: None
Source Type: Journal
DOI: 10.1093/annonc/mdh360 Document Type: Letter |
Times cited : (2)
|
References (6)
|